NO20072401L - Doseringsregime for en S1P-reseptoragonist - Google Patents

Doseringsregime for en S1P-reseptoragonist

Info

Publication number
NO20072401L
NO20072401L NO20072401A NO20072401A NO20072401L NO 20072401 L NO20072401 L NO 20072401L NO 20072401 A NO20072401 A NO 20072401A NO 20072401 A NO20072401 A NO 20072401A NO 20072401 L NO20072401 L NO 20072401L
Authority
NO
Norway
Prior art keywords
receptor agonist
dosage regimen
dosing
standard
administered
Prior art date
Application number
NO20072401A
Other languages
English (en)
Norwegian (no)
Inventor
John M Kovarik
Silke Appel-Dingemanse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072401(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20072401L publication Critical patent/NO20072401L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
NO20072401A 2004-11-29 2007-05-10 Doseringsregime for en S1P-reseptoragonist NO20072401L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29
PCT/US2005/043044 WO2006058316A1 (en) 2004-11-29 2005-11-28 Dosage regimen of an s1p receptor agonist

Publications (1)

Publication Number Publication Date
NO20072401L true NO20072401L (no) 2007-06-22

Family

ID=36046868

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20072401A NO20072401L (no) 2004-11-29 2007-05-10 Doseringsregime for en S1P-reseptoragonist
NO20121305A NO20121305L (no) 2004-11-29 2012-11-06 Doseringsregime for en S1P-reseptoragonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20121305A NO20121305L (no) 2004-11-29 2012-11-06 Doseringsregime for en S1P-reseptoragonist

Country Status (21)

Country Link
US (3) US20090275553A1 (es)
EP (3) EP1819326B1 (es)
JP (4) JP2008521827A (es)
KR (4) KR20070085465A (es)
CN (2) CN102600472A (es)
AU (1) AU2005309378B2 (es)
BR (1) BRPI0518674A2 (es)
CA (1) CA2589265A1 (es)
ES (1) ES2495690T3 (es)
IL (2) IL183134A0 (es)
MA (1) MA29034B1 (es)
MX (1) MX2007006373A (es)
NO (2) NO20072401L (es)
NZ (2) NZ554720A (es)
PL (1) PL1819326T3 (es)
PT (1) PT1819326E (es)
RU (2) RU2478384C2 (es)
SG (2) SG158096A1 (es)
TN (1) TNSN07209A1 (es)
WO (1) WO2006058316A1 (es)
ZA (1) ZA200703328B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781595A1 (en) 2004-08-13 2007-05-09 Praecis Pharmaceuticals Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
NZ554720A (en) * 2004-11-29 2011-04-29 Novartis Ag Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol)
JO2655B1 (en) * 2005-09-09 2012-06-17 نوفارتيس ايه جي Treatment of autoimmune diseases
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US20100093672A1 (en) * 2007-05-04 2010-04-15 Yves-Alain Barde Use of s1p receptor modulator
HRP20170246T4 (hr) * 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
JPWO2009142195A1 (ja) * 2008-05-20 2011-09-29 杏林製薬株式会社 寛解導入維持剤
AU2009273259B2 (en) 2008-07-23 2013-05-02 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
MX2011001832A (es) 2008-08-18 2011-04-28 Novartis Ag Compuestos para el tratamiento de neuropatias perifericas.
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
RS53041B (sr) * 2008-12-18 2014-04-30 Novartis Ag Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
ES2531831T3 (es) * 2008-12-18 2015-03-20 Novartis Ag Forma polimórfica del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxilico
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
PT4098256T (pt) * 2008-12-22 2025-04-10 Novartis Ag Regime de dosagem para um agonista do recetor de s1p
SG10201406168RA (en) * 2009-09-29 2014-11-27 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
WO2011138398A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
ES2751920T3 (es) 2011-01-07 2020-04-02 Novartis Ag Formulaciones inmunosupresoras
CN103889408A (zh) * 2011-10-21 2014-06-25 诺华股份有限公司 S1p受体调节剂或激动剂的剂量方案
LT2885266T (lt) 2012-08-17 2020-07-10 Actelion Pharmaceuticals Ltd (2z,5z)-5-(3-chlor-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ono gamybos būdas ir šiame procese naudojamas tarpinis junginys
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
IL292529A (en) 2019-10-31 2022-06-01 Idorsia Pharmaceuticals Ltd Combination of cxcr7 antagonist with s1p1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
ES2230571T3 (es) * 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
DK1002792T3 (da) 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
WO2002078766A2 (en) * 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
HUP0303454A3 (en) * 2001-04-02 2005-12-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60231522D1 (de) * 2001-06-08 2009-04-23 Novartis Ag Behandlung und vorbeugung von insulin-produzierende zelltransplantatabstossung
US6963012B2 (en) * 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
PT1431284E (pt) 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
DE60329073D1 (de) * 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
PL408347A1 (pl) * 2002-09-24 2014-08-18 Novartis Ag Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012461A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
NZ554720A (en) * 2004-11-29 2011-04-29 Novartis Ag Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol)
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
IL223502A0 (en) 2013-02-03
NZ554720A (en) 2011-04-29
RU2012141951A (ru) 2014-04-10
AU2005309378A1 (en) 2006-06-01
EP1819326B1 (en) 2014-07-02
KR20150028858A (ko) 2015-03-16
SG158096A1 (en) 2010-01-29
NZ590054A (en) 2012-07-27
ZA200703328B (en) 2008-08-27
CN102600472A (zh) 2012-07-25
PT1819326E (pt) 2014-09-25
JP2012107059A (ja) 2012-06-07
KR20070085465A (ko) 2007-08-27
TNSN07209A1 (en) 2008-11-21
NO20121305L (no) 2007-06-22
EP2384749A1 (en) 2011-11-09
HK1109057A1 (en) 2008-05-30
CN101068536B (zh) 2012-12-05
US20090275553A1 (en) 2009-11-05
US20150087720A1 (en) 2015-03-26
US20120071446A1 (en) 2012-03-22
MX2007006373A (es) 2007-06-20
KR20130041385A (ko) 2013-04-24
BRPI0518674A2 (pt) 2008-12-02
JP2013129664A (ja) 2013-07-04
RU2007124327A (ru) 2009-01-10
WO2006058316A1 (en) 2006-06-01
AU2005309378B2 (en) 2010-02-11
PL1819326T3 (pl) 2014-12-31
EP2359821A1 (en) 2011-08-24
CA2589265A1 (en) 2006-06-01
SG187468A1 (en) 2013-02-28
KR20140095109A (ko) 2014-07-31
IL183134A0 (en) 2008-04-13
ES2495690T3 (es) 2014-09-17
MA29034B1 (fr) 2007-11-01
JP2015061883A (ja) 2015-04-02
RU2478384C2 (ru) 2013-04-10
EP1819326A1 (en) 2007-08-22
CN101068536A (zh) 2007-11-07
JP2008521827A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
NO20072401L (no) Doseringsregime for en S1P-reseptoragonist
Yang et al. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine
JO3044B1 (ar) نظام تناول جرعة لمنبه مستقبل s1p
TN2011000272A1 (en) Dosage regimen for a s1p agonist
de Avila et al. Relationship between levels of neuropeptide S ubstance P in periodontal disease and chronic pain: A literature review
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
Aral et al. Therapeutic effects of systemic vitamin k2 and vitamin d3 on gingival inflammation and alveolar bone in rats with experimentally induced periodontitis
Guo et al. Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
Hu et al. Panax notoginseng saponins prevent bone loss by promoting angiogenesis in an osteoporotic mouse model
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
CO2017012766A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
Sun et al. Activation of PGC‐1α‐dependent mitochondrial biogenesis supports therapeutic effects of silibinin against type I diabetic periodontitis
NO20092473L (no) Kombinasjon
ZA202000028B (en) Use of vibegron to treat overactive bladder
Lei et al. Angiotensin‐(1–7) protects cardiomyocytes against high glucose‐induced injuries through inhibiting reactive oxygen species‐activated leptin–p38 mitogen‐activated protein kinase/extracellular signal‐regulated protein kinase 1/2 pathways, but not the leptin–c‐Jun N‐terminal kinase pathway in vitro
Awosanya et al. The impacts of COVID-19 on musculoskeletal health
Tyrovola The “Mechanostat” Principle and the Osteoprotegerin—OPG/RANKL/RANK System PART II. The Role of the Hypothalamic—Pituitary Axis
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
Ezzat et al. The ability of H 1 or H 2 receptor antagonists or their combination in counteracting the glucocorticoid‐induced alveolar bone loss in rats
Lee et al. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator‐activated receptors
Li et al. Sclerostin regulation: a promising therapy for periodontitis by modulating alveolar bone
Kim et al. Salicylideneamino‐2‐thiophenol enhances osteogenic differentiation through the activation of MAPK pathways in multipotent bone marrow stem cell

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application